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Hereditary p16-Leiden Mutation in a Patient
with Multiple Head and Neck Tumors
To the Editor:
Recent studies have shown that most Dutch familieswith
atypical multiple-mole melanoma (FAMMM) have a 19-
bp germline deletion (p16-Leiden) in exon 2 of the p16
gene (p16 [MIM 600160]) (Gruis et al. 1995; van der
Velden et al. 1999, 2001). Incomplete penetrance and
variable clinical expression in p16-Leiden carriers point
to the fact that other genetic mechanisms can compen-
sate for the p16 loss of function (Gruis et al. 1995).
Indeed, van der Velden et al. (2001) reported in the Jour-
nal that variants in the melanocortin-1 receptor modify
the risk of melanoma in p16-Leiden carriers. It is inter-
esting that, apart from reports on simultaneous pancre-
atic tumors, other cancer types have never been found
in such families with p16-Leiden (Gruis et al. 1995).
Recently, we found a hereditary heterozygous p16-
Leiden mutation in a man who neither smoked more
than five cigarettes daily nor abused alcohol, initially
diagnosed at age 54 years, who simultaneously devel-
oped three carcinomas of the pharynx and oral cavity.
The patient showed a familial accumulation of tumor
diseases. Both of his parents and his only sister died of
cancer very early (the mother of gynecologic cancer, the
father of liver carcinoma, and the sister of leukemia).
Dutch relatives are not known.
DNA from tumors and blood was extracted according
to a standard protocol (Sambrook et al. 1989).Mutation
analysis of exon 1 and exon 2 of the p16 gene was done
by PCR-SSCP sequencing as described by Schneider-
Stock et al. (1998).
The p16-Leiden mutation was found in the hetero-
zygous constitution in all three tumors and in the blood
of the patient. We investigated all DNA samples for p16
promotor methylation to check the status of the retained
wild-type allele and, thus, to assess the real functional
significance of this finding. The methylation status of the
p16 promotor was determined by methylation-specific
PCR (Herman et al. 1996). The primer sequences for
the unmethylated reactions were (sense) 5′-TTA TTA
GAG GGT GGG GTG GAT TGT-3′ and (antisense) 5′-
CAA CCC CAA ACC ACA ACC ATA A-3′, which am-
plify a 151-bp product. The primer sequences for the
methylated reaction were (sense) 5′-TTA TTA GAG
GGT GCG GAT CGC-3′ and (antisense) 5′-GAC CCC
GAA CCG CGA CCG TAA-3′, which amplify a 150-bp
product. The two forward primers were labeled with
FAM dye. PCR was done using 1/10 of bisulfite reaction
and a MasterAmp Optimization Kit (Biozym) in an au-
tomated thermocycler (PTC 200) according to the man-
ufacturer’s instructions. PCR products were analyzed us-
ing an ABI310 sequencer (injection time between 20–30
s, Pop 4, dRhodamine Matrix standard ABI Prism [Per-
kin Elmer]). The p16 promotor was methylated in all
three tumor samples but not in the blood of the patient
(fig. 1).
This result led us to suggest a loss of p16 protein
expression and, thus, a complete loss of p16 tumor sup-
pressor function. For p16 immunohistochemistry, a
monoclonal mouse antibody to p16 (1:100 dilution,
Quartett) was used according to the manufacturer’s in-
structions. Indeed, all tumor sectionswere immunohisto-
chemically p16-negative. The third tumor showed an
additional gross rearrangement in the p53 gene (75-bp
insertion in exon 4).
This is the first report on p16-Leiden mutation in oro-
laryngeal carcinomas, although p16 alterations are very
common in this tumor type (50% p16 promotor methyl-
ation [Bittencourt Rosas et al. 2001], 30% p16 muta-
tions [Esteller et al. 2001a; Poi et al. 2001]). Because of
the heterozygous p16-Leiden constitution, our proband
was a suitable model for studying the type of p16 in-
activation in the three metachronous carcinomas. To
date, the methylation status of p16-Leiden carriers has
never been checked. To the best of our knowledge, this
is one of the only a few clear examples that aberrant
promotor methylation might function as the “second
genetic hit” in a familial cancer syndrome. Whereas no
methylation could be recognized in the blood of the pa-
tient’s DNA, all three tumors showed inactivation of the
retained wild-type allele, with the somatic event being
aberrant promotor methylation. There are only a few
reports demonstrating the role of promotor methylation
for biallelic gene inactivation (Grady et al. 2000; Esteller
et al. 2001b). Furthermore, it has to be mentioned that
the p16-Leiden mutation should also affect the p14ARF
transcript, because alternative splicing of the first exon
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Figure 1 Analysis of p16INK4 promotor methylation on ABI310
Prism. Methylated (left arrow) and unmethylated (right arrow) signals
can be detected between the 150-bp and the 160-bp ROX matrix
standards. There is a near-equal amplification of unmethylated and
methylated DNA in the three head and neck tumors but nomethylation
in the blood DNA of the patient; blp blood DNA; tu1–tu3p tumors
1–3, respectively.
and common downstream exons permit this locus to
encode two different products that regulate the cell cycle
via two distinct pathways.
It is noteworthy that contact with the patient began
five months before the actual date of examination when
the patient attended a talk. His presence was not because
of symptoms of a tumor but because of genetic findings.
This early meeting led to discovery of the tumor of the
tongue while the tumor was still in a less-advanced stage.
Therefore, the tumor could be easily resected, leaving
the tongue almost unaffected. Consequently, the patient
is now in good physical condition (Karnofsky 70%–
80%). The patient was informed about the hereditary
mutation and was included in the risk program for up-
per-abdominal screening because p16-Leiden mutation
has been reported to be a risk factor for developing
pancreatic carcinoma (Lal et al. 2000; Vasen et al. 2000;
Lynch et al. 2002).
We think that regarding head and neck cancer, our
data is novel and may have consequences for further
studies of families with FAMMM.
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